rosiglitazone has been researched along with Cardiac Diseases in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (58.33) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Huang, Q; Li, D; Li, T; Li, Z; Lu, Y; Pan, Z; Wu, H; Yang, T; Yang, W; Zhan, L; Zhang, G; Zhuang, Y | 1 |
Blaner, WS; Drosatos, K; Goldberg, IJ; Homma, S; Jiang, H; Khan, RS; Schulze, PC; Son, NH; Trent, CM | 1 |
Mishra, P; Rath, SK; Singh, SV; Srivastava, P; Sultana, S; Verma, AK | 1 |
Faich, GA; Stemhagen, A | 1 |
Ambery, P; Pandya, B | 1 |
Finck, BN; Gropler, RJ; Herrero, P; Schechtman, KB; Sharp, T; Shoghi, KI; Welch, MJ | 1 |
Gautier, JF; Lesven, S; Maréchaud, R | 1 |
Le Feuvre, C | 1 |
De Flines, J; Paquot, N; Scheen, AJ | 1 |
D'Arrigo, T | 1 |
3 review(s) available for rosiglitazone and Cardiac Diseases
Article | Year |
---|---|
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
Topics: Animals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucagon-Like Peptide 1; Heart Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
[Heart, diabetes and glitazones].
Topics: Contraindications; Diabetes Mellitus, Type 2; Edema; Heart; Heart Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazolidinediones | 2004 |
[What about the controversy regarding rosiglitazone].
Topics: Advisory Committees; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
9 other study(ies) available for rosiglitazone and Cardiac Diseases
Article | Year |
---|---|
Involvement of lncR-30245 in Myocardial Infarction-Induced Cardiac Fibrosis Through Peroxisome Proliferator-Activated Receptor-γ-Mediated Connective Tissue Growth Factor Signalling Pathway.
Topics: Animals; Benzamides; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Heart Diseases; Mice, Inbred C57BL; Models, Animal; Myocardial Infarction; PPAR gamma; Pyridines; RNA, Long Noncoding; Rosiglitazone; Stroke Volume; Transforming Growth Factor beta1; Up-Regulation | 2019 |
Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice.
Topics: Animals; Fatty Acids; Heart Diseases; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; PPAR gamma; Rosiglitazone; Sepsis; Thiazolidinediones; Ventricular Dysfunction, Left | 2013 |
Rosiglitazone induces cardiotoxicity by accelerated apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cell Differentiation; Cell Line; Cell Survival; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Heart Diseases; Heme Oxygenase (Decyclizing); Hypoglycemic Agents; Male; Mice; Myocytes, Cardiac; NADPH Oxidases; NF-E2-Related Factor 2; Nitric Oxide Synthase; Oxidative Phosphorylation; Oxidative Stress; Protein Kinase C-delta; Rats; Rosiglitazone; Signal Transduction; Superoxides; Thiazolidinediones; Time Factors | 2014 |
Cardiac safety of diabetes therapies and postmarketing requirements.
Topics: Heart Diseases; Humans; Hypoglycemic Agents; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2008 |
The new rosiglitazone story: its place today in type 2 diabetes management.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heart Diseases; Humans; Hypoglycemic Agents; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Glucose; Glucose Transport Proteins, Facilitative; Heart Diseases; Hemodynamics; Hypoglycemic Agents; Male; Metformin; Myocardium; Oxidation-Reduction; Phenotype; Positron-Emission Tomography; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors | 2009 |
Alternative medications exist for controversial diabetes drug. Patients concerned about rosiglitazone (Avandia) should talk with their doctors about other options.
Topics: Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones | 2010 |
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2004 |
Glitazones and your heart, revisited.
Topics: Heart Diseases; Heart Failure; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |